The Latest Breaking News on Pharma

A new report by an anti-transnational crime group has identified the core chemical components of kush, a synthetic drug that has swept through Sierra Leone and the region in the past few years.

Elon Musk is vowing yet again to fire any federal workers who don’t respond to an email asking them to list five things they accomplished last week

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. Read further on Dynamite News:

Mr Schumacher was named CEO in 2023 following the retirement of Alan Jope but has now stepped down in a surprise move

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….